The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acute Myeloid Leukemia-Global Market Insights and Sales Trends 2024
Synopsis
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection.
The global Acute Myeloid Leukemia market size is expected to reach US$ 3158.1 million by 2029, growing at a CAGR of 13.0% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Myeloid Leukemia in various end use industries. The expanding demands from the Hospital, Retails Drug Stores, Ambulatory Care Centers and Oncology Centers, are propelling Acute Myeloid Leukemia market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Myeloid Leukemia, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Myeloid Leukemia market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Myeloid Leukemia market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Myeloid Leukemia sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Myeloid Leukemia covered in this report include Celgene Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation, Sunesis Pharmaceuticals, Abbvie, Astellas Pharma and CTI Biopharma Corp, etc.
The global Acute Myeloid Leukemia market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Abbvie
Astellas Pharma
CTI Biopharma Corp
Global Acute Myeloid Leukemia market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Myeloid Leukemia market, Segment by Type:
Chemotherapy
Radiation Therapy
Stem Cell Transplant
Targeted Therapy
Others
Global Acute Myeloid Leukemia market, by Application
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Myeloid Leukemia companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection.
The global Acute Myeloid Leukemia market size is expected to reach US$ 3158.1 million by 2029, growing at a CAGR of 13.0% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Myeloid Leukemia in various end use industries. The expanding demands from the Hospital, Retails Drug Stores, Ambulatory Care Centers and Oncology Centers, are propelling Acute Myeloid Leukemia market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Myeloid Leukemia, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Myeloid Leukemia market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Myeloid Leukemia market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Myeloid Leukemia sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Myeloid Leukemia covered in this report include Celgene Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation, Sunesis Pharmaceuticals, Abbvie, Astellas Pharma and CTI Biopharma Corp, etc.
The global Acute Myeloid Leukemia market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Abbvie
Astellas Pharma
CTI Biopharma Corp
Global Acute Myeloid Leukemia market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Myeloid Leukemia market, Segment by Type:
Chemotherapy
Radiation Therapy
Stem Cell Transplant
Targeted Therapy
Others
Global Acute Myeloid Leukemia market, by Application
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Myeloid Leukemia companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Acute Myeloid Leukemia
1.1 Acute Myeloid Leukemia Market Overview
1.1.1 Acute Myeloid Leukemia Product Scope
1.1.2 Acute Myeloid Leukemia Market Status and Outlook
1.2 Global Acute Myeloid Leukemia Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Acute Myeloid Leukemia Market Size by Region (2018-2029)
1.4 Global Acute Myeloid Leukemia Historic Market Size by Region (2018-2023)
1.5 Global Acute Myeloid Leukemia Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Acute Myeloid Leukemia Market Size (2018-2029)
1.6.1 North America Acute Myeloid Leukemia Market Size (2018-2029)
1.6.2 Europe Acute Myeloid Leukemia Market Size (2018-2029)
1.6.3 Asia-Pacific Acute Myeloid Leukemia Market Size (2018-2029)
1.6.4 Latin America Acute Myeloid Leukemia Market Size (2018-2029)
1.6.5 Middle East & Africa Acute Myeloid Leukemia Market Size (2018-2029)
2 Acute Myeloid Leukemia Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Radiation Therapy
2.1.3 Stem Cell Transplant
2.1.4 Targeted Therapy
2.1.5 Others
2.2 Global Acute Myeloid Leukemia Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Acute Myeloid Leukemia Historic Market Size by Type (2018-2023)
2.2.2 Global Acute Myeloid Leukemia Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Acute Myeloid Leukemia Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Acute Myeloid Leukemia Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Acute Myeloid Leukemia Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Acute Myeloid Leukemia Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Acute Myeloid Leukemia Revenue Breakdown by Type (2018-2029)
3 Acute Myeloid Leukemia Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Retails Drug Stores
3.1.3 Ambulatory Care Centers
3.1.4 Oncology Centers
3.1.5 Clinics
3.2 Global Acute Myeloid Leukemia Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Acute Myeloid Leukemia Historic Market Size by Application (2018-2023)
3.2.2 Global Acute Myeloid Leukemia Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Acute Myeloid Leukemia Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Acute Myeloid Leukemia Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Acute Myeloid Leukemia Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Acute Myeloid Leukemia Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Acute Myeloid Leukemia Revenue Breakdown by Application (2018-2029)
4 Acute Myeloid Leukemia Competition Analysis by Players
4.1 Global Acute Myeloid Leukemia Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia as of 2022)
4.3 Date of Key Players Enter into Acute Myeloid Leukemia Market
4.4 Global Top Players Acute Myeloid Leukemia Headquarters and Area Served
4.5 Key Players Acute Myeloid Leukemia Product Solution and Service
4.6 Competitive Status
4.6.1 Acute Myeloid Leukemia Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Celgene Corporation
5.1.1 Celgene Corporation Profile
5.1.2 Celgene Corporation Main Business
5.1.3 Celgene Corporation Acute Myeloid Leukemia Products, Services and Solutions
5.1.4 Celgene Corporation Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.1.5 Celgene Corporation Recent Developments
5.2 Cephalon
5.2.1 Cephalon Profile
5.2.2 Cephalon Main Business
5.2.3 Cephalon Acute Myeloid Leukemia Products, Services and Solutions
5.2.4 Cephalon Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.2.5 Cephalon Recent Developments
5.3 Clavis Pharma
5.3.1 Clavis Pharma Profile
5.3.2 Clavis Pharma Main Business
5.3.3 Clavis Pharma Acute Myeloid Leukemia Products, Services and Solutions
5.3.4 Clavis Pharma Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.3.5 Eisai Recent Developments
5.4 Eisai
5.4.1 Eisai Profile
5.4.2 Eisai Main Business
5.4.3 Eisai Acute Myeloid Leukemia Products, Services and Solutions
5.4.4 Eisai Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.4.5 Eisai Recent Developments
5.5 Genzyme Corporation
5.5.1 Genzyme Corporation Profile
5.5.2 Genzyme Corporation Main Business
5.5.3 Genzyme Corporation Acute Myeloid Leukemia Products, Services and Solutions
5.5.4 Genzyme Corporation Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.5.5 Genzyme Corporation Recent Developments
5.6 Sunesis Pharmaceuticals
5.6.1 Sunesis Pharmaceuticals Profile
5.6.2 Sunesis Pharmaceuticals Main Business
5.6.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Products, Services and Solutions
5.6.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.6.5 Sunesis Pharmaceuticals Recent Developments
5.7 Abbvie
5.7.1 Abbvie Profile
5.7.2 Abbvie Main Business
5.7.3 Abbvie Acute Myeloid Leukemia Products, Services and Solutions
5.7.4 Abbvie Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.7.5 Abbvie Recent Developments
5.8 Astellas Pharma
5.8.1 Astellas Pharma Profile
5.8.2 Astellas Pharma Main Business
5.8.3 Astellas Pharma Acute Myeloid Leukemia Products, Services and Solutions
5.8.4 Astellas Pharma Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.8.5 Astellas Pharma Recent Developments
5.9 CTI Biopharma Corp
5.9.1 CTI Biopharma Corp Profile
5.9.2 CTI Biopharma Corp Main Business
5.9.3 CTI Biopharma Corp Acute Myeloid Leukemia Products, Services and Solutions
5.9.4 CTI Biopharma Corp Acute Myeloid Leukemia Revenue (US$ Million) & (2018-2023)
5.9.5 CTI Biopharma Corp Recent Developments
6 North America
6.1 North America Acute Myeloid Leukemia Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acute Myeloid Leukemia Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acute Myeloid Leukemia Market Dynamics
11.1 Acute Myeloid Leukemia Industry Trends
11.2 Acute Myeloid Leukemia Market Drivers
11.3 Acute Myeloid Leukemia Market Challenges
11.4 Acute Myeloid Leukemia Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
